

=> d his

(FILE 'HOME' ENTERED AT 11:28:52 ON 19 NOV 2007)

FILE 'HCAPLUS' ENTERED AT 11:29:01 ON 19 NOV 2007
E US20040072800/PN 25

L1 1 S E3

FILE 'STNGUIDE' ENTERED AT 11:29:35 ON 19 NOV 2007

FILE 'REGISTRY' ENTERED AT 11:31:04 ON 19 NOV 2007
L2 10 S 7585-39-9 OR 9059-74-9 OR 10016-20-3 OR 10016-20-3 OR 12619-7FILE 'HCAPLUS' ENTERED AT 11:31:16 ON 19 NOV 2007
L3 134513 S L2
L4 1 S L1 AND L3

FILE 'STNGUIDE' ENTERED AT 11:31:36 ON 19 NOV 2007

FILE 'REGISTRY' ENTERED AT 11:33:04 ON 19 NOV 2007
L5 3 S 7585-39-9 OR 10016-20-3 OR 12619-70-4
L6 6 S 9059-74-9 OR 25322-68-3 OR 25322-69-4 OR 39444-87-6 OR 116236FILE 'HCAPLUS' ENTERED AT 11:37:02 ON 19 NOV 2007
L7 22765 S L5
L8 112678 S L6
L9 1598 S L7 AND L8

FILE 'STNGUIDE' ENTERED AT 11:37:20 ON 19 NOV 2007

FILE 'HCAPLUS' ENTERED AT 11:38:16 ON 19 NOV 2007

FILE 'HCAPLUS' ENTERED AT 11:38:28 ON 19 NOV 2007
L10 58264 S ?DIISOCYAN?
L11 9 S L10 AND L9

FILE 'STNGUIDE' ENTERED AT 11:39:01 ON 19 NOV 2007

FILE 'HCAPLUS' ENTERED AT 11:40:21 ON 19 NOV 2007
L12 166185 S ?ISOCYAN?
L13 15 S L9 AND L12
L14 6 S L13 NOT L11

FILE 'STNGUIDE' ENTERED AT 11:41:22 ON 19 NOV 2007

FILE 'REGISTRY' ENTERED AT 11:44:19 ON 19 NOV 2007
L15 5 S 9059-74-9 OR 25322-69-4 OR 39444-87-6 OR 116236-05-6 OR 67661FILE 'HCAPLUS' ENTERED AT 11:44:25 ON 19 NOV 2007
L16 16641 S L15
L17 140 S L7 AND L16
L18 133 S L17 NOT (L13)
L19 61 S L18 AND 1800<=PY<=2002

FILE 'STNGUIDE' ENTERED AT 11:45:22 ON 19 NOV 2007

FILE 'REGISTRY' ENTERED AT 11:46:00 ON 19 NOV 2007
L20 1 S 9059-74-9
L21 1 S 25322-69-4
L22 1 S 39444-87-6
L23 1 S 116236-05-6
L24 1 S 676619-87-7

FILE 'HCAPLUS' ENTERED AT 11:47:00 ON 19 NOV 2007

L25 216 S L20
L26 16333 S L21
L27 108 S L22
L28 16 S L23
L29 9 S L24
L30 1 S L7 AND L25
L31 140 S L7 AND L26
L32 1 S L7 AND L27
L33 1 S L7 AND L28
L34 1 S L7 AND L29
L35 1 S L30 AND L32 AND L33 AND L34

FILE 'STNGUIDE' ENTERED AT 11:48:32 ON 19 NOV 2007

FILE 'REGISTRY' ENTERED AT 11:49:23 ON 19 NOV 2007

L36 31240 S CYCLODEXTRIN

FILE 'HCAPLUS' ENTERED AT 11:49:34 ON 19 NOV 2007

L37 31592 S L36
L38 1 S L37 AND L25
L39 157 S L37 AND L26
L40 2 S L37 AND L27
L41 1 S L37 AND L28
L42 1 S L37 AND L29
L43 1 S L40 NOT L41

L14 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:259760 HCAPLUS

DOCUMENT NUMBER: 146:297297

TITLE: Hydrophobically modified polyrotaxanes with good solubility in organic solvents and crosslinked polyrotaxanes

INVENTOR(S): Ito, Kohzo; Araki, Jun; Suzuki, Tatsuya; Yamanaka, Masahiko; Watanabe, Kentarou

PATENT ASSIGNEE(S): Nissan Motor Co., Ltd., Japan; The University of Tokyo

SOURCE: PCT Int. Appl., 45pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007026578	A1	20070308	WO 2006-JP316457	20060823
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM JP 2007091938 A 20070412 JP 2005-284925 20050929 PRIORITY APPLN. INFO.: JP 2005-251508 A 20050831 JP 2005-284925 A 20050929				

AB Title hydrophobically modified polyrotaxanes comprise cyclic mols., a linear mol. which pierces the cyclic mols. to form a clathrate therewith, and blocking groups which are disposed at both ends of this linear mol. and prevent the cyclic mols. from being released. The cyclic mols. are a cyclodextrin, and all or part of the hydroxy groups of the cyclodextrin have been modified with a hydrophobic modifying group. The crosslinked polyrotaxanes are obtained by bonding the hydrophobically modified polyrotaxanes to a polymer through any of the cyclic mols. Thus, 10 g polyethylene glycol, 100 mg TEMPO, and 1 g sodium bromide were dissolved in 100 mL water, 5 mL 5% an aqueous sodium hypochlorous acid solution was added therein and stirred at room temperature, 3 g of the resulting carboxy-terminated polyethylene glycol and 12 g α -cyclodextrin were dissolved in 50 mL water at 70° and stirred, and stored at 4° overnight to give an inclusion compound, 14 g of which was dissolved in 20 mL a mixture of 75 volume% DMF and 25 volume% dimethylsulfoxide, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate 3, 1-hydroxybenzotriazole 1, and adamantane 1.4 g, and 1.25 mL diisopropylethylamin dissolved in 10 mL DMF was added therein and stirred, 500 mg of the resulting polyrotaxane was dissolved in 50 mL 1M an aqueous sodium hydroxide solution, 3.83 g propylene oxide was added therein and stirred, and reacted with stannous 2-ethylhexanoate to give a hydrophobically-modified polyrotaxane, showing good solubility in toluene, Et acetate, and acetone.

IT 10016-20-3DP, α -Cyclodextrin, rotaxane compds. with carboxy-terminated polyoxyalkylenes, reaction products with adamantanamine, propylene oxide, and tin ethylhexanoate 25322-68-3DP, Polyethylene glycol, carboxy-terminated, rotaxane compds. with dextrin, reaction products with adamantanamine, propylene oxide, and tin

ethylhexanoate


RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(hydrophobically modified polyrotaxanes with good solubility in organic solvents and crosslinked polyrotaxanes)


RN 10016-20-3 HCAPLUS

CN α -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.



RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)IT 10016-20-3, α -Cyclodextrin 25322-68-3,

Polyethylene glycol


RL: RCT (Reactant); RACT (Reactant or reagent)

(hydrophobically modified polyrotaxanes with good solubility in organic solvents and crosslinked polyrotaxanes)


RN 10016-20-3 HCAPLUS

CN α -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.




RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



IT 7585-39-9D, β -Cyclodextrin, rotaxanes compds. with linear
 polymers 12619-70-4D, Cyclodextrins, rotaxanes compds. with
 linear polymers
 RL: TEM (Technical or engineered material use); USES (Uses)
 (hydrophobically modified polyrotaxanes with good solubility in organic
 solvents and crosslinked polyrotaxanes)

RN 7585-39-9 HCAPLUS
 CN β -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.



RN 12619-70-4 HCAPLUS
CN Cyclodextrin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:259283 HCAPLUS

DOCUMENT NUMBER: 146:274813

TITLE: Modified hydrophilic polyrotaxane and crosslinked
polyrotaxane

INVENTOR(S): Ito, Kohzo; Araki, Jun; Suzuki, Tatsuya; Yamanaka,
Masahiko; Watanabe, Kentarou

PATENT ASSIGNEE(S): Nissan Motor Co., Ltd., Japan; The University of Tokyo

SOURCE: PCT Int. Appl., 45pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007026594	A1	20070308	WO 2006-JP316575	20060824
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

JP 2007063412 A 20070315 JP 2005-251441 20050831
 PRIORITY APPLN. INFO.: JP 2005-251441 A 20050831
 AB Polyrotaxane having a cyclic mol. and a linear mol. with piercing through the cyclic mol., and capping groups at both ends of the linear mols. is made with hydrophilic modification on hydroxyl group in cyclodextrin as cyclic mols. Thus, a polyrotaxane was obtained from carboxy-terminated PEG and cyclodextrin, and then capped with adamantanamine and modified by forming hydroxypropyl ether.
 IT 10016-20-3, α -Cyclodextrin 25322-68-3, Poly(ethylene glycol)
 RL: RCT (Reactant); RACT (Reactant or reagent)
 ((crosslinked) hydrophilic rotaxane with PEG and cyclodextrin)
 RN 10016-20-3 HCAPLUS
 CN α -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1203238 HCAPLUS
 DOCUMENT NUMBER: 145:491049
 TITLE: Cationic crosslinked starch-containing starch compositions useful for papermaking and coating
 INVENTOR(S): Anderson, Kevin Ray; Garlie, David Edward
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006254738	A1	20061116	US 2005-130382	20050516
WO 2006124869	A1	20061123	WO 2006-US18879	20060516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-130382 A 20050516
 AB The comps. contain 0.001-99.999% cationic crosslinked starch. Thus, 440 g Altracharge 145 cationic crosslinked dent corn starch was slurried in water to a 5% starch suspension, added with 4.4 g cationic gum guar 2-hydroxy-3-(trimethylammonio)-Pr ether chloride, jet cooked at 230° F in a pilot jet cooker to give a 99:1 cooked starch paste/cationic gum guar composition
 IT 12619-70-4, Cyclodextrin 25322-68-3, Polyethylene oxide
 RL: POF (Polymer in formulation); TEM (Technical or engineered material use); USES (Uses)
 (cationic crosslinked starch-containing starch comps. useful for papermaking and coating)
 RN 12619-70-4 HCAPLUS
 CN Cyclodextrin (CA INDEX NAME)
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)




L14 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1069797 HCAPLUS
 DOCUMENT NUMBER: 145:408846
 TITLE: Method for forming a porous polishing pad from unexpanded microspheres in a polymer matrix
 INVENTOR(S): James, David B.; Kulp, Mary Jo; Roberts, John V. H.
 PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 21pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006226567	A1	20061012	US 2006-398265	20060404
PRIORITY APPLN. INFO.:			US 2005-670361P	P 20050411
AB The present invention provides a method of forming a chemical mech. polishing pad comprising providing a polymeric matrix premixed with fluid-filled unexpanded microspheres, curing the polymeric matrix by reaction with an isocyanate, and heating the polymeric matrix and the microspheres to expand the microspheres. The efficient method uses a unique premix apparatus to provide pads from an essentially endless variety of polymer matrix and microsphere materials with improved performance. It allows continuous reaction-injection molding or casting.				
IT 12619-70-4, Cyclodextrin 25322-68-3, Polyethylene glycol				
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); TEM (Technical or engineered material use); PROC (Process); USES (Uses)				
(microspheres; method for forming a porous polishing pad from unexpanded microspheres in a polymer matrix)				
RN 12619-70-4 HCAPLUS				
CN Cyclodextrin (CA INDEX NAME)				
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***				
RN 25322-68-3 HCAPLUS				
CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)				




L14 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:772703 HCAPLUS
 DOCUMENT NUMBER: 133:336024
 TITLE: In-situ forming hydrogels from polyethylene glycols
 INVENTOR(S): Hubbell, Jeffrey A.; Kornfield, Julia A.; Tae, Giyoong
 PATENT ASSIGNEE(S): California Institute of Technology, USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064977	A1	20001102	WO 2000-US11691	20000426
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1173517	A1	20020123	EP 2000-931980	20000426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1999-133164P	P 19990426
			WO 2000-US11691	W 20000426


- AB A hydrogel precursor composition comprises: (a) a polymer, the polymer comprising a water soluble polymer domain with at least two hydrophobic interacting groups attached thereto, the polymer capable of assembling into a hydrogel under physiol. conditions; and (b) a phys. chemical protecting group, the phys. chemical protecting group preventing gelation of the hydrogel precursor composition. The invention features materials and methods for the liquid to solid transition of an injectable pre-hydrogel composition to a hydrogel. These methods can be carried out in situ.
- IT 25322-68-3DP, Poly (ethylene glycol), reaction products with isocyanates and fluorinated alcs.
 RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (in-situ forming hydrogels from polyethylene glycols)
- RN 25322-68-3 HCAPLUS
- CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



- IT 7585-39-9, β -Cyclodextrin 10016-20-3,
 α -Cyclodextrin
 RL: MOA (Modifier or additive use); USES (Uses)
 (in-situ forming hydrogels from polyethylene glycols)
- RN 7585-39-9 HCAPLUS
- CN β -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





RN 10016-20-3 HCAPLUS
 CN α -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:597199 HCAPLUS

DOCUMENT NUMBER: 105:197199

TITLE: Readily absorbable pharmaceutical composition

INVENTOR(S): Kondo, Nobuo; Nakajima, Tsunetaka; Watanabe, Masahiro; Yokoyama, Kazumasa; Suyama, Tadakazu; Haga, Takahiro; Yamada, Nobutoshi; Sugi, Hideo; Koyanagi, Toru

PATENT ASSIGNEE(S): Ishihara Sangyo Kaisha, Ltd., Japan; Green Cross Corp.

SOURCE: Eur. Pat. Appl., 29 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 192263	A2	19860827	EP 1986-102217	19860220
EP 192263	A3	19870204		
EP 192263	B1	19920729		
R: BE, DE, FR, GB, IT, NL, SE				
JP 61191623	A	19860826	JP 1985-32365	19850220
JP 61205257	A	19860911	JP 1985-44737	19850308
JP 01056065	B	19891128		
US 4727077	A	19880223	US 1986-823521	19860129

US 4849425	A	19890718	US 1986-824088	19860130
ZA 8600775	A	19861029	ZA 1986-775	19860203
GB 2171695	A	19860903	GB 1986-2792	19860205
GB 2171695	B	19890105		
AU 8653285	A	19860911	AU 1986-53285	19860206
AU 593233	B2	19900208		
CA 1266473	A1	19900306	CA 1986-501576	19860211
CA 1260396	A1	19890926	CA 1986-501662	19860212
FR 2577551	A1	19860822	FR 1986-2147	19860218
FR 2577551	B1	19880415		
DD 243025	A5	19870218	DD 1986-287134	19860218
CH 671576	A5	19890915	CH 1986-642	19860218
CN 86101087	A	19870225	CN 1986-101087	19860219
CN 1013196	B	19910717		
SU 1500156	A3	19890807	SU 1986-4023808	19860219
DK 8600802	A	19860821	DK 1986-802	19860220
DK 163124	B	19920120		
DK 163124	C	19920609		
BR 8603945	A	19880517	BR 1986-3945	19860819
PRIORITY APPLN. INFO.:			JP 1985-32365	A 19850220
			JP 1985-44737	A 19850308
OTHER SOURCE(S):		CASREACT 105:197199; MARPAT 105:197199		
GI				




AB An antitumor composition comprises I (R = halo, NO₂; R₁, R₂ = H, halo; R₃ = halo, CF₃; A = CH, N) as an active agent and at least one additive selected from the group consisting of a cyclodextrin, polyethylene glycol and refined oil. The additives improve water solubility and absorbability of I through the skin or mucous membranes. Thus, 5-bromo-2-chloropyrimidine was reacted with 4-amino-2-chlorophenol to give 4-(5-bromo-2-pyrimidinylloxy)-3-chloroaniline, which was reacted with 2-nitrobenzoylisocyanate to give I (R = NO₂, R₁ = Cl, R₂ = H, R₃ = Br, A = N) (II). II was dispersed in a suppository base containing PEG 1000 90, PEG 4000 4, and PEG 400 6% by weight, and formed into a suppository.

IT 7585-39-9 10016-20-3 25322-68-3
 RL: BIOL (Biological study)
 (antitumor composition containing nitrobenzoylpyrimidinylloxyphenylurea and, absorbability enhancement in)


RN 7585-39-9 HCAPLUS
 CN β-Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.



RN 10016-20-3 HCAPLUS
 CN α -Cyclodextrin (CA INDEX NAME)


Absolute stereochemistry.



43619/11/2007

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



L9 ANSWER 1 OF 1598 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:1243222 HCAPLUS
 TITLE: Lyophilized therapeutic peptibody formulations
 INVENTOR(S): Callahan, William J.; Remmele, Richard L., Jr.;
 Ratnaswamy, Gayathri; Latypov, Ramil F.; Liu,
 Dingjiang
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 185pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007124090	A2	20071101	WO 2007-US9712	20070420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-793997P P 20060421
 US 2007-788697 A 20070419

AB The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody. In general, a pharmaceutically active peptide is attached to an antibody Fc fragment through the N-terminus of the peptide, C-terminus of the peptide, or both, and the resulting structure may be further modified with a covalently attached water-soluble polymer. The pharmaceutically active peptides are selected from the group comprising: interleukin-1 antagonists, erythropoietin mimetics, thrombopoietin mimetics, selectin antagonists, Mdm/hdm antagonists, SH3 antagonist, urokinase receptor antagonists, myostatin inhibitors, etc. The stable compns. comprise a buffer, a bulking agent, a stabilizing agent, and optionally a surfactant.


IT INDEXING IN PROGRESS

IT 25322-68-3D, Polyethylene glycol, conjugates

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (lyophilized therapeutic peptibody formulations)

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



IT 12619-70-4, Cyclodextrin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (stabilizing agent; lyophilized therapeutic peptibody formulations)

RN 12619-70-4 HCAPLUS

CN Cyclodextrin (CA INDEX NAME)

=> d 19 ibib abs hitstr 2-9

L9 ANSWER 2 OF 1598 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:1242874 HCAPLUS
 TITLE: Osmotic drug delivery system comprising prostacyclin
 INVENTOR(S): Kidane, Argaw; Bhatt, Padmanabh P.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 16pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007254032	A1	20071101	US 2006-412100	20060427
WO 2007127216	A2	20071108	WO 2007-US9969	20070426


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-412100 A 20060427
 AB This invention relates to an oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in a elementary osmotic pump delivery system and at least one release enhancing agent. Thus, osmotic tablet was prepared comprising treprostinil diethanolamine 0.65%, xylitol 41.0%, Maltrin M150 (wet) 1.4%, Maltrin M150 (dry) 48.20%, sodium lauryl sulfate 5.0%, and meglumine 3.0%.
 IT 12619-70-4, Cyclodextrins 25322-68-3
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PRP (Properties); USES (Uses)
 (osmotic drug delivery system comprising prostacyclin)
 RN 12619-70-4 HCAPLUS
 CN Cyclodextrin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



L9 ANSWER 3 OF 1598 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:1237328 HCAPLUS
 TITLE: Oral pharmaceutical composition comprising lipase inhibitor and lipophilic oil absorbent
 INVENTOR(S): Park, Jin Woo; Bin, Sung Ah; Lee, Jeong A.; Kim, Jung

Ju
 PATENT ASSIGNEE(S): AmorePacific Corporation, S. Korea
 SOURCE: PCT Int. Appl., 25pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007123338	A1	20071101	WO 2007-KR1938	20070420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: KR 2006-35687 A 20060420

AB This invention provides an oral pharmaceutical composition comprising (i) a lipase inhibitor; (ii) a lipophilic oil absorbent selected from the group consisting of hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof; and (iii) a pharmaceutically acceptable additive, and a method for preparing the formulation. The formulation of the present invention can minimize side effects such as oily spotting, fatty/oily stool, abdominal distension and flatus, and thus it can be advantageously used for preventing or treating obesity and hyperlipemia. Thus, orlistat-containing granules were prepared comprising orlistat 120.0 mg, microcryst. cellulose 93.60 mg, sodium starch glycolate 7.20 mg, polyvinylpyrrolidone K30 12.00 mg, sodium lauryl sulfate 7.20 mg, and talc 0.24 mg. Hydrogenated castor oil-containing granules comprising hydrogenated castor oil 405 g and microcryst. cellulose 45 g were prepared and coated with a mixture of Eudragit L30D55 463.75 g, talc 70 g, and tri-Et citrate 14 g. The orlistat-containing granules 240.24 mg were mixed with hydrogenated castor oil-containing granules 3 mg and polyethylene oxide 200 mg, and filled into a sachet. The coated granules comprising hydrogenated castor oil as a lipophilic oil absorbent can adsorb unabsorbed oil after the activation of orlistat or increase the viscosity thereof to minimize such side effects as oily spotting.

IT 12619-70-4D, Cyclodextrin, derivs. 25322-68-3,

Polyethylene oxide 25322-68-3D, alkyl ether

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of oral composition comprising lipase inhibitor and lipophilic oil absorbent for prevention or treatment of obesity and hyperlipemia)


RN 12619-70-4 HCAPLUS

CN Cyclodextrin (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 1598 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:1232396 HCAPLUS
 TITLE: Modified-release preparations containing oxcarbazepine
 and derivatives thereof
 INVENTOR(S): Kidane, Argaw; Bhatt, Padmanabh P.; Edwards, Kevin
 PATENT ASSIGNEE(S): Supernus Pharmaceuticals, Inc., USA
 SOURCE: Can. Pat. Appl., 43pp.
 CODEN: CPXXEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2597740	A1	20071026	CA 2007-2597740	20070413
US 2007254033	A1	20071101	US 2007-734874	20070413
WO 2007127630	A1	20071108	WO 2007-US66643	20070413

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
 GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
 KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
 MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-794837P P 20060426
 WO 2007-US66643 W 20070413

AB Controlled-release compns. of oxcarbazepine and derivs. thereof for
 once-a-day administration and release in gastrointestinal tract are
 described. The compns. comprise solubility- and/or release-enhancing agents to
 provide tailored drug release profiles, preferably sigmoidal release
 profile. Methods of treatment comprising the inventive compns. are also
 described. Thus, tablets with sigmoidal release profile were prepared by
 wet granulation containing oxcarbazepine 60, Compritol 888ATO 9.5, Prosolv
 HD90 9.8, Kollidon 25 10, Carbopol 971P 10, magnesium stearate 0.5, and
 FD&C Blue #11.2%, resp. The pharmacokinetics of the granules prepared were
 evaluated in a randomized, single dose, crossover study in healthy
 humans,, showing Tmax of 6.5 h, Cmax of 0.248 $\mu\text{g/mL}$, AUClast of 3.0
 h $\cdot\mu\text{g/mL}$, and relative bioavailability of 53%.


IT 7585-39-9D, β -Cyclodextrin, hydroxypropyl derivs.
 25322-68-3, PEG400

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (controlled-release preps. of oxcarbazepine and its derivs. comprising
 solubilizers and release-enhancing agents)

RN 7585-39-9 HCAPLUS
 CN β -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



L9 ANSWER 5 OF 1598 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:1228898 HCAPLUS
 TITLE: Composition comprising antiviral and antimicrobial agent for treating viral infection at smallpox vaccination site
 INVENTOR(S): Rolf, David
 PATENT ASSIGNEE(S): Lectec Corporation, USA
 SOURCE: U.S., 36pp., Cont.-in-part of U.S. Ser. No. 688,445, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7288265	B1	20071030	US 2003-338809	20030108
WO 2004062600	A2	20040729	WO 2004-US392	20040108
WO 2004062600	A3	20041104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ

US 2007026056	A1	20070201	US 2006-535214	20060926
PRIORITY APPLN. INFO.:			US 2000-688445	B2 20001016
			US 2003-338809	A 20030108


AB This invention relates to an adhesive patch wherein the patch includes a porous backing having a front side and a back side. The patch also includes a therapeutic formulation located on the front side of the backing. The backing includes a flexible sheet of water insol. porous material. The therapeutic formulation includes a combination of a antiviral agent useful for treating a viral infection in a mammal (e.g., human), a medicament that relieves topical discomfort, an adhesive, and a solvent. The solvent can preferably include a fragrance. Thus, composition was prepared containing glycerin 48.2%, lysine 2.0%, propylene glycol 2.0%, Eucalyptus oil 1.6%, adhesive 3.0%, lidocaine 3.8%, aloe vera gel 0.5%, karaya 26.0%, deionized water 10.5%, Quat-15 0.1%, camphor 2.0%, and vitamin E 0.3%.

IT 7585-39-9D, β -Cyclodextrin, hydroxypropyl esthers
 25322-68-3D, PEG, dicaprylate/dicaprate glycerides
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition comprising antiviral and antimicrobial agent for treating viral infection at smallpox vaccination site)

RN 7585-39-9 HCAPLUS
 CN β -Cyclodextrin (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A





RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 1598 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:1218033 HCAPLUS
 TITLE: Pharmaceutical composition for treating vaginal diseases and its preparation
 INVENTOR(S): Sun, Yaozhi
 PATENT ASSIGNEE(S): Henan Wanxi Pharmaceutical Co., Ltd., Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 25pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101057892	A	20071024	CN 2006-10076207	20060419

PRIORITY APPLN. INFO.: CN 2006-10076207 20060419

AB The title pharmaceutical composition in forms of external-use effervescent tablet, lotion and suppository is prepared from Phellodendron amurense 200-600, Rheum rhubarbarum 200-600, Salvia miltiorrhiza 200-600, mastic(processed) 60-120, myrrh(processed) 60-120, Lithospermum 200-600, Cyclina sinensis powder 100-300 and borneol 10-30 part. The pharmaceutical composition is prepared by (1) extracting Phellodendron amurense and Rheum rhubarbarum with ethanol to obtain extraction liquor; (2) extracting Salvia miltiorrhiza and Lithospermum with ethanol to obtain extraction liquor; (3) extracting mastic and myrrh with water to obtain volatile oil, dewatering to obtain paint-yellow oil, filtrating distilled medicinal liquor, extracting medicinal dregs with water to obtain extraction liquor, mixing with extraction liquor obtained in step (1) to obtain mixed extraction liquor; (4) pulverizing Cyclina sinensis shell to obtain Cyclina sinensis powder; (5) mixing extraction liquor obtained in step (2) and (3), decompression concentrating, adding Cyclina sinensis powder, mixing, drying, pulverizing; (6) dissolving β -cyclodextrin in distilled water, adding volatile oil obtained in step (2), stirring, filtrating, drying, grinding to obtain volatile oil- β -cyclodextrin clathrate compound; (7) preparing borneol- β -cyclodextrin clathrate compound in the same way; (8) mixing extract powder obtained in step (5) with β -cyclodextrin clathrate compound, dividing into two parts, mixing one part with hexanedioic acid, sodium CM-cellulose, Tween 80, low-substituted hydroxypropyl cellulose, PEG-6000, sodium dodecyl sulfate, micropowder silica gel and talcum powder, adding 3-10 wt% acrylic resin IV ethanol solution, softening, drying to obtain

acidic granule, mixing the other part with sodium hydrogen carbonate, sodium carboxym. The invention also relates to preparation of lotion. The inventive product has effects of clearing heat, drying dampness, killing pests, alleviating itching, expelling swelling and regenerating muscle, and can be used for preparing medicaments for treating vaginal diseases, such as mycotic vaginitis and trichomonas vaginitis.

IT INDEXING IN PROGRESS

IT 7585-39-9, β -Cyclodextrin 25322-68-3, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses).


(pharmaceutical composition for treating vaginal diseases and its preparation)

RN 7585-39-9 HCAPLUS

CN β -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



L9 ANSWER 7 OF 1598 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:1217674 HCAPLUS
 TITLE: Method for preparing food additive with aged fragrance
 and its application
 INVENTOR(S): Jiao, Jialiang; Song, Puqiu; Li, Yaquan; Lou, Zitian;
 Chen, Guanghui; Lin, Xiang
 PATENT ASSIGNEE(S): Yunnan Longrun Pharmaceutical Co., Ltd., Peop. Rep.
 China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 12pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101057623	A	20071024	CN 2007-10065917	20070529

PRIORITY APPLN. INFO.: CN 2007-10065917 20070529

AB The title method comprises the steps of: (1) adding stack-fermented thea
 assamica into a distillation tank, (2) adding water 1-20 weight times thea
 assamica, and soaking (3) boiling for 0.5-20 h, and cooling the generated
 steam via circulation water to obtain distilled liquid, (4) transporting to an
 extraction tank, adding an extractor 0.1-10 weight times the distilled liquid, and
 extracting to obtain aged-fragrant component in organic phase, (5) standing to
 demix, removing the water phase, removing residual water in the organic phase
 with an organic drier, filtering to sep. the drier, and calcining the drier
 at 200°C to recover, (6) adding the organic phase into a concentration tank,
 and vacuum-concentration at 0-50°C to recover organic solvent and obtain
 aged-fragrant volatile oil, and (7) mixing with a vehicle at a ratio of
 1:100, and sieving with a 60-200 mesh sieve to obtain granulated or powdered
 food additive with aged fragrance. The method has the advantages of
 simple process and low cost. The obtained food additive has high safety
 and no toxicity, and can be used in solid or liquid drink, buccal tablets,
 chewable tablet, and effervescent tablets.


IT INDEXING IN PROGRESS

IT 7585-39-9, β -Cyclodextrin 25322-68-3, Polyethylene
 glycol
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (method for preparing food additive with aged fragrance and its
 application)


RN 7585-39-9 HCAPLUS

CN β -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)




L9 ANSWER 8 OF 1598 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:1215756 HCAPLUS
 DOCUMENT NUMBER: 147:474750
 TITLE: Oral sustained release formulation containing
 venlafaxine
 INVENTOR(S): Hsiao, Fang-Hsiung; Changchien, Ya-Ching
 PATENT ASSIGNEE(S): Taiwan
 SOURCE: U.S. Pat. Appl. Publ., 10pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	----	-----	-----

US 2007248669 A1 20071025 US 2006-410017 20060425
 PRIORITY APPLN. INFO.: US 2006-410017 20060425
 AB The present invention relates to an oral sustained release formulation comprising a core, a medicinal layer containing venlafaxine or a pharmaceutically acceptable salt of venlafaxine and a release-modulating layer containing a release-modulating agent. A formulation contains a core, a medicinal layer comprising venlafaxine-HCl, Et cellulose, tri-Et citrate, titania, talc, and water and a release-modulating layer comprising Et cellulose, di-Bu phthalate, titania, talc and water.
 IT 12619-70-4, Cyclodextrin 25322-68-3, Peg
 RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral sustained release formulation containing venlafaxine)
 RN 12619-70-4 HCAPLUS
 CN Cyclodextrin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



L9 ANSWER 9 OF 1598 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:1176086 HCAPLUS
 DOCUMENT NUMBER: 147:433666
 TITLE: Pre-mixed, ready-to-use IV bolus composition comprising nicardipine
 INVENTOR(S): Gupta, Supriya; Mi, Yanli; Zamiri, Camellia
 PATENT ASSIGNEE(S): PDI Biopharma, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 27pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007244166	A1	20071018	US 2007-737067	20070418
US 2007249689	A1	20071025	US 2007-788076	20070418
WO 2007121483	A2	20071025	WO 2007-US66897	20070418
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2007123984	A2	20071101	WO 2007-US9549	20070418
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,			

MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2006-793074P

P 20060418

AB This invention relates to ready-to-use premixed bolus injection
 pharmaceutical comps. of nicardipine or a pharmaceutically acceptable
 salt and methods for use in treating cardiovascular and cerebrovascular
 conditions. For example, nicardipine hydrochloride 0.3 mg/mL formulation
 was made in 30 mM Na-acetate buffer, pH 4.5, containing captisol 0-3% w/v and
 evaluated for their potential for precipitation at the site of injection.

IT 7585-39-9D, β -Cyclodextrin, sulfobutyl ether

25322-68-3, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(pre-mixed, ready-to-use IV bolus composition comprising nicardipine)

RN 7585-39-9 HCAPLUS

CN β -Cyclodextrin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



=> fil stng

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2004:305169 HCAPLUS
 DOCUMENT NUMBER: 140:304722
 TITLE: Method for improving viscosity of hydrophobic thickeners for polymer-containing aqueous systems
 INVENTOR(S): Zhang, Lifeng
 PATENT ASSIGNEE(S): Rohm and Haas Company, USA
 SOURCE: Eur. Pat. Appl., 14 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1408051	A1	20040414	EP 2003-255812	20030917
EP 1408051	B1	20070725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
IN 2003MU01017	A	20050715	IN 2003-MU1017	20030929
CA 2443667	A1	20040411	CA 2003-2443667	20030930
BR 2003004303	A	20040831	BR 2003-4303	20030930
AU 2003248472	A1	20040429	AU 2003-248472	20031001
US 2004072800	A1	20040415	US 2003-677436	20031002 <--
MX 2003PA09254	A	20040428	MX 2003-PA9254	20031009
KR 2004033273	A	20040421	KR 2003-70699	20031010
CN 1497021	A	20040519	CN 2003-10100650	20031010
PRIORITY APPLN. INFO.:			US 2002-417854P	P 20021011

IT 7585-39-9DP, β -Cyclodextrin, Me derivs., complexes with hydrophobically-modified ethoxylated urethanes 9059-74-9DP, HDI-polyethylene glycol copolymer, hydrophobically modified, complex with cyclodextrins 10016-20-3DP, α -Cyclodextrin, Me derivs., complexes with hydrophobically-modified ethoxylated urethanes 12619-70-4DP, Cyclodextrin, ethoxylated or propoxylated, complexes with hydrophobically-modified ethoxylated urethanes 17465-86-0DP, γ -Cyclodextrin, Me derivs., complexes with hydrophobically-modified ethoxylated urethanes 25322-68-3DP, Polyethylene glycol, ethers with cyclodextrin, complexes with hydrophobically-modified ethoxylated urethanes 25322-69-4DP, Polypropylene glycol, ethers with cyclodextrin, complexes with hydrophobically-modified ethoxylated urethanes 39444-87-6DP, Hydrogenated MDI-polyethylene glycol copolymer, hydrophobically modified, complex with cyclodextrins 116236-05-6DP, hydrophobically modified, complex with cyclodextrins
 RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
 (method for improving viscosity of hydrophobic thickeners for polymer-containing aqueous systems)

RN 7585-39-9 HCAPLUS
 CN β -Cyclodextrin (CA INDEX NAME)


Absolute stereochemistry.



RN 9059-74-9 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy-, polymer with
 1,6-diisocyanatohexane (CA INDEX NAME)


CM 1

CRN 25322-68-3
 CMF (C2 H4 O)_n H2 O
 CCI PMS




CM 2

CRN 822-06-0
 CMF C8 H12 N2 O2



RN 10016-20-3 HCAPLUS
 CN α -Cyclodextrin (CA INDEX NAME)


Absolute stereochemistry.




RN 12619-70-4 HCAPLUS
 CN Cyclodextrin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 17465-86-0 HCAPLUS
 CN γ -Cyclodextrin (CA INDEX NAME)



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)




RN 25322-69-4 HCAPLUS
 CN Poly[oxy(methyl-1,2-ethanediyl)], α -hydro- ω -hydroxy- (CA INDEX NAME)



RN 39444-87-6 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy-, polymer with 1,1'-methylenebis[4-isocyanatocyclohexane] (CA INDEX NAME)


CM 1

CRN 25322-68-3
 CMF (C2 H4 O)_n H2 O
 CCI PMS



CM 2

CRN 5124-30-1
 CMF C15 H22 N2 O2



RN 116236-05-6 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy-, polymer with Desmodur W (9CI) (CA INDEX NAME)


CM 1

CRN 79103-62-1
 CMF Unspecified
 CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 25322-68-3
 CMF (C2 H4 O)_n H2 O
 CCI PMS



IT 676619-87-7, Rhoplex SG 30
RL: POF (Polymer in formulation); TEM (Technical or engineered material use); USES (Uses)
(method for improving viscosity of hydrophobic thickeners for polymer-containing aqueous systems)
RN 676619-87-7 HCAPLUS
CN Rhoplex SG 30 (CA INDEX NAME)

ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:305169 HCAPLUS
 DOCUMENT NUMBER: 140:304722
 TITLE: Method for improving viscosity of hydrophobic thickeners for polymer-containing aqueous systems
 INVENTOR(S): Zhang, Lifeng
 PATENT ASSIGNEE(S): Rohm and Haas Company, USA
 SOURCE: Eur. Pat. Appl., 14 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1408051	A1	20040414	EP 2003-255812	20030917
EP 1408051	B1	20070725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
IN 2003MU01017	A	20050715	IN 2003-MU1017	20030929
CA 2443667	A1	20040411	CA 2003-2443667	20030930
BR 2003004303	A	20040831	BR 2003-4303	20030930
AU 2003248472	A1	20040429	AU 2003-248472	20031001
US 2004072800	A1	20040415	US 2003-677436	20031002 <--
MX 2003PA09254	A	20040428	MX 2003-PA9254	20031009
KR 2004033273	A	20040421	KR 2003-70699	20031010
CN 1497021	A	20040519	CN 2003-10100650	20031010

PRIORITY APPLN. INFO.: US 2002-417854P P 20021011

AB A composition for reduced viscosity hydrophobic thickener system for a polymer-containing aqueous system comprises (a) a cyclodextrin-containing compound having a hydrophobic cavity of a predetd. size (e.g., methyl- β -cyclodextrin) and (b) a hydrophobically modified associative thickener containing ≥ 1 terminal phobe of a size capable of complexing with the hydrophobic cavity of the cyclodextrin-containing compound [e.g., hydrophobically modified polyethoxylated urethane (HEUR) synthesized using DES W (hydrogenated MDI)], wherein at least a portion of the cyclodextrin-containing compound is complexed with the hydrophobically modified associative in such a way that at least a portion of at least one of the phobe at least partially fills the hydrophobic cavity.

AN 2004:305169 HCAPLUS

DN 140:304722

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1408051	A1	20040414	EP 2003-255812	20030917
EP 1408051	B1	20070725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			US 2002-417854P	P 20021011
IN 2003MU01017	A	20050715	IN 2003-MU1017	20030929
			US 2002-417854P	P 20021011
CA 2443667	A1	20040411	CA 2003-2443667	20030930
			US 2002-417854P	P 20021011
BR 2003004303	A	20040831	BR 2003-4303	20030930
			US 2002-417854P	P 20021011
AU 2003248472	A1	20040429	AU 2003-248472	20031001
			US 2002-417854P	P 20021011
US 2004072800	A1	20040415	US 2003-677436	20031002 <--
			US 2002-417854P	P 20021011
MX 2003PA09254	A	20040428	MX 2003-PA9254	20031009
			US 2002-417854P	P 20021011
KR 2004033273	A	20040421	KR 2003-70699	20031010

43619/11/2007

	CN 1497021	A	20040519	US 2002-417854P	P	20021011
				CN 2003-10100650		20031010
				US 2002-417854P	A	20021011
RN	7585-39-9DP					
RN	9059-74-9DP					
RN	10016-20-3DP					
RN	10016-20-3DP					
RN	12619-70-4DP					
RN	17465-86-0DP					
RN	17465-86-0DP					
RN	25322-68-3DP					
RN	25322-69-4DP					
RN	39444-87-6DP					
RN	116236-05-6DP					
RN	676619-87-7					

=> fil stng